New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
05:59 EDTBLUEbluebird bio announces data from HGB-205 clinical study
bluebird bio on Saturday released initial clinical data from its HGB-205 clinical study of its LentiGlobin BB305 product candidate in beta-thalassemia major subjects. The company said the clinical update provided on two subjects treated in the prior LG001 Study using the prior lentiviral HPV569 product candidate; Subject 3 remains blood transfusion independent 72 months after being transplanted with the lentiviral HPV569 product candidate; Subjects 3 and 4 are producing 2.7 g/dL and 0.4 g/dL of therapeutic beta A-T87Q-globin post-transplant, respectively; No drug product related adverse events were reported in the LG001 Study. The company sees reporting additional data from the HGB-205 Study and from our ongoing Northstar Study in late 2014.
News For BLUE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 23, 2014
10:02 EDTBLUEOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:16 EDTBLUEbluebird bio initiated with a Buy at Roth Capital
Target $50.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use